GRF Grifols, S.A.

BME · ES · Healthcare · Drug Manufacturers - General · grifols.com

9.648EUR+0.86%Mkt Cap: 7.14B $P/E: 14.62Today

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates thr…

Industry Peers

Drug Manufacturers - General

Screen all

LLY

Eli Lilly and Company Common Stock

$1.02TUSDP/E 38.4

JNJ

Johnson & Johnson Common Stock

$617.01BUSDP/E 29.7

ABBV

AbbVie Inc. Common Stock

$464.43BUSDP/E 74.2

MRK

Merck & Company, Inc. Common Stock (new)

Novartis AG Common Stock

AstraZeneca PLC Ordinary Shares

Amgen Inc. - Common Stock

Gilead Sciences, Inc. - Common Stock

$179.47BUSD

NVO

Novo Nordisk A/S Common Stock

$164.79BUSDP/E 9.4

PFE

Pfizer, Inc. Common Stock

$158.45BUSDP/E 36.6

BMY

Bristol-Myers Squibb Company Common Stock

$124.91BUSDP/E 13.5

SNY

Sanofi - American Depositary Shares

$95.65BUSDP/E 21.8

GSK

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Key Statistics

Company

Market Cap7.14B USD

Enterprise Value19.28B USD

Revenue (TTM)8.07B USD

Gross Profit3.11B USD

Net Income (TTM)436.96M USD

Revenue/Share10.85 EUR

Last Price9.648 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees25.3K

CountryES

SectorHealthcare

IndustryDrug Manufacturers - General

ISIN—

Valuation

P/E (Trailing)14.62

P/E (Forward)8.37

PEG0.24

EV/EBITDA10.78

EV/Revenue2.39

P/S0.87

P/B1.17

EPS (TTM)0.66

EPS (Forward)1.14

52W Range

8.43231% of range12.39

52W High12.39 EUR

52W Low8.432 EUR

Profitability

Gross Margin38.00%

Oper. Margin15.90%

EBITDA Margin22.17%

Profit Margin5.34%

ROE7.63%

ROA2.04%

Growth

Revenue Growth-0.90%

Earnings Growth32.90%

Cash Flow & Leverage

Operating CF1.14B USD

CapEx (TTM)459.78M USD

FCF Margin7.72%

FCF Yield8.73%

Net Debt9.59B USD

Net Debt/EBITDA5.36

Balance Sheet

Debt/Equity1.81

Current Ratio2.37

Quick Ratio0.70

Book Value/Sh8.15 EUR

Cash/Share0.79 EUR

Dividends

Fwd Div Rate0.08 EUR

Trail. Div Rate0.00 EUR

Div. Yield0.86%

5Y Avg Yield1.33%

Payout Ratio35.19%

Ex-Div DateJun 30, 2026

Pay Date—

Splits

Last Split2:1

Split DateJan 4, 2016

Analyst Consensus

Rating2.0 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)14.76 EUR

Upside (mean)+53.0%

Target Range9.000 EUR – 23.00 EUR

9.000+53.0% to mean23.00

# Analysts12

Ownership

Shares Out.422.36M

Float418.22M

Insiders31.19%

Institutions37.62%

Technical

SMA 509.872 (-2.3%)

SMA 2009.794 (-1.5%)

Beta1.19

S&P 52W Chg14.58%

Avg Vol (30d)733.98K

Avg Vol (10d)1.10M

Technical Indicators

RSI (14)45.9

MACD-0.0732

MACD Signal-0.0735

MACD Hist.+0.0004

BB Upper9.970 EUR

BB Middle9.657 EUR

BB Lower9.344 EUR

BB Width6.48%

ATR (14)0.2225 EUR

Vol Ratio (20d)0.83x